Novavax on Wednesday said the U.S. Food and Drug Administration has asked the company to commit to produce more data on its ...

Novavax Inc. shares rose after US regulators asked for more data on its Covid vaccine, signaling the shot may be on a path to ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The FDA has asked Novavax to commit to producing post-marketing data of its Covid vaccine, the clearest example yet that the bar is higher for advancing new vaccines under HHS Secretary Robert F.

The current US domestic news highlights involve President Trump's stance on Federal Reserve Chair Jerome Powell, cybercrime ...

Investing.com -- Novavax (NASDAQ: NVAX) shares surged 13% following the biotechnology company’s optimism about its Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA).

The move comes amid HHS Secretary Robert F. Kennedy Jr.’s decision to force out the top official responsible for reviewing ...

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, declaring that single antigen ...

Novavax's traditional protein-based COVID shot offers an alternative technology to messenger RNA-based rivals from Pfizer-BioNTech and Moderna, but has failed to make a mark in the U.S. vaccine market ...

In the wake of unprecedented workforce cuts at the FDA, former Commissioner Scott Gottlieb and an unnamed former CBER ...

Novavax has shared positive preliminary results from a real-world study of its JN.1-adapted COVID-19 vaccine. The SHIELD-Utah ...

Novavax shifts to a partnership-focused strategy with a $500M Sanofi deal. Despite regulatory and competitive risks. See why ...